Ask AI
ProCE Banner Activity

Emerging Therapeutic Strategies and Biomarker-Driven Care in mCRPC

Clinical Thought

In this expert commentary, the evolving landscape of mCRPC is examined, with a focus on the biological rationale, clinical evidence, and implementation challenges of novel targeted therapies and precision medicine approaches.

Released: May 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Novartis Pharmaceuticals Corporation.

AstraZeneca

Novartis Pharmaceuticals Corporation

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurses, pharmacists, physician associates, and other community and specialist healthcare professionals involved in the management of patients with castration-resistant prostate cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanism of action and rationale for novel therapies under investigation in mCRPC

  • Evaluate new data on novel agents and therapeutic approaches for patients with mCRPC

  • Identify patients with mCRPC who may be eligible for ongoing clinical trials of novel therapies

  • Implement strategies to support equitable access to clinical trials of novel therapies in Black and other underserved patient populations with mCRPC

Disclosure

Primary Author

Alicia K. Morgans, MD, MPH, FASCO: consultant/advisor/speaker: Astellas, AstraZeneca, Bayer, Curium, Dendreon, Johnson & Johnson, Lantheus, Merck, Novartis, Pfizer, Telix, Tolmar; researcher: Astellas, Bayer, Curium, Johnson & Johnson, Novartis, Pfizer, Telix.

Charles J. Ryan, MD: consultant/advisor/speaker: Arsenal Biosciences, Bayer, Johnson & Johnson, Novartis, Vir Biotechnology; other financial or material support: Lilly.